Skip to content
Lipum.
Lipum.

Press release -

Lipum raises SEK 85 million and become listed on Nasdaq First North

Umeå-based biopharmaceutical company Lipum has been working towards a stock exchange listing since 2018 – and now the moment has finally arrived.

On Thursday, April 22, shares in Lipum will be traded on the Nasdaq First North Growth Market for the very first time. The company will ring Nasdaq's opening bell, which has been specially transported to Umeå, to mark the occasion.

Lipum has developed a biological drug candidate which aims to offer better treatments for children with rheumatism. Pre-clinical studies have shown very promising results, and production development is ongoing.

“We will begin clinical trials in the spring of 2022, which means that we are at a late stage of our pre-clinical development. In parallel with the clinical development we aim to produce additional pre-clinical data relating to more diseases than just rheumatism. Our goal then is to establish collaborations with larger companies for the treatment of various chronic inflammatory diseases,” says Einar Pontén, CEO of Lipum.

Preparations for Lipum’s stock exchange listing began at the end of 2018, and have played a major role in the company and on its decision-making processes ever since. During the autumn of 2020 these preparations intensified considerably.

“We have raised approximately SEK 85 million through a new share issue, with the opportunity to receive an additional SEK 60 million in August 2022 via share options. In addition to gaining access to venture capital, we are also becoming more widely known. And now, as we become a public company, we must strive to become even better. It’s something that really motivates us,” says Einar Pontén.

Thursday, April 22 will be the first trading day for Lipum shares on the Nasdaq First North Growth Market, and staff will gather outside its office at Tvistevägen 48 in Umeå to celebrate the launch.

“The bell ceremony will be held at 09:00 to officially begin the trading day. Because of the global pandemic Nasdaq has produced a traveling bell that is being sent to Umeå. The opening bell will also be rung on the stationary bell at the same time in Stockholm, and the entire ceremony can be followed via Zoom,” says Einar Pontén.

He continues:

“We are of course elated to have reached this milestone. It is proof that we are a well-organised company with a clear business idea that many others want to have an interest in”.

You can follow Lipum’s stock exchange bell ceremony at https://lipum.se/nasdaq-klocka/

For more information please contact:

Einar Pontén, CEO
einar.ponten@lipum.se
+ 46 70-578 34 95

Related links

Topics

Categories


Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Contacts

Tomas Ruuth

Tomas Ruuth

Press contact Head of PR & Communications PR & Communications 072-4024697 www.ubi.se

Related content

Einar Pontén, CEO of Lipum, and Professor Anders Fasth.

Expert advisor enters Lipum

​Now Umeå company Lipum brings more expertise to the company. Professor Anders Fasth steps in as an advisor in the development of medicines for inflammatory diseases. “It is very gratifying that he joins the team,” says Einar Pontén, CEO of Lipum.

Dr Kristian Sandberg, Director of the Drug Discovery and Development platform at SciLifeLab.

Biotech Expert Joins Lipum Board

Dr Kristian Sandberg, Director of the Drug Discovery and Development platform at SciLifeLab, has joined the board of Umeå-based biotech company Lipum. “Kristian has extensive experience in drug development. We are absolutely delighted to announce his appointment”, says Ulf Björklund, Chairman of the Board at Lipum.

We grow ideas that can change the world

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Umeå Biotech Incubator
Umeå Biotech Incubator

Tvistevägen 48C
907 36 Umeå
Sweden